Oral Pemphigus Vulgaris: Recognizing Mouth Blisters and Ulcers

Understanding Oral Pemphigus Vulgaris and Mucosal Anatomy

Oral pemphigus vulgaris is a chronic, potentially life-threatening autoimmune blistering disorder that primarily targets the mucous membranes of the oral cavity before frequently spreading to the skin. The oral cavity is lined by stratified squamous epithelium, a protective cellular barrier composed of keratinocytes tightly bound to one another. In healthy oral mucosa, these structural cells are anchored together by microscopic bridge-like structures known as desmosomes. Desmosomes rely on specialised cadherin adhesion proteins, predominantly desmoglein 3 (Dsg3) and desmoglein 1 (Dsg1), to maintain tissue integrity under the mechanical stress of mastication, swallowing, and speech.

In pemphigus vulgaris, the immune system mistakenly manufactures pathogenic autoantibodies directed against these desmoglein proteins. The resultant breakdown in cell-to-cell adhesion—a process termed intraepithelial acantholysis—causes the upper layers of the oral lining to detach from the deeper layers. Because the separation occurs high within the epithelium just above the basal cell layer (suprabasal clefting), the roof of each resulting blister is exceptionally thin and fragile. Consequently, intact pemphigus vulgaris mouth blisters are rarely seen during routine oral examination, as everyday friction causes them to rupture rapidly, leaving behind exquisitely tender, non-healing raw erosions.

Underlying Causes, Autoimmunity, and Predisposing Factors

The fundamental cause of pemphigus vulgaris is an autoimmune dysregulation wherein circulating immunoglobulin G (IgG) autoantibodies, particularly IgG1 and IgG4, bind directly to desmoglein 3 located in the mucosal epithelium. This binding initiates intracellular signalling cascades that dismantle desmosomal architecture and sterically hinder intercellular cohesion. While the exact trigger for this autoimmune response remains uncertain, robust genetic predispositions have been identified worldwide. Strong associations exist with specific human leukocyte antigen (HLA) class II alleles, notably HLA-DRB1*0402 and HLA-DQB1*0503, which are particularly prevalent among individuals of Mediterranean, Middle Eastern, and Ashkenazi Jewish ancestry.

Environmental and physiological co-factors can also precipitate or exacerbate disease activity. Certain thiol-containing pharmaceuticals (such as penicillamine and captopril), non-steroidal anti-inflammatory drugs, and distinct viral infections have been documented as potential triggers. In South Asian populations, regional practices involving the consumption of areca nut, paan, gutka, and heavily spiced or abrasive diets can cause recurrent mechanical and chemical micro-trauma to the oral mucosa. While these habits do not initiate the underlying autoimmune state, they significantly aggravate tissue vulnerability, delay mucosal healing, and confound clinical diagnosis in primary dental settings.

Clinical Presentation: Recognising Pemphigus Vulgaris Mouth Blisters

In up to 80 percent of cases, the mouth is the primary site of involvement, often preceding cutaneous lesions by several months or even a year. Patients typically present with widespread, painful, and persistent erosions rather than obvious fluid-filled vesicles. When pemphigus vulgaris mouth blisters do form, they are flaccid and rupture almost immediately under normal masticatory pressure. The resulting lesions appear as irregularly shaped, shallow, red ulcerations covered by a loose, yellowish-white fibrinous slough, frequently exhibiting ragged, peeling epithelial margins that detach upon gentle manipulation.

Lesions can develop on any mucosal surface, but they demonstrate a predilection for sites subjected to routine mechanical friction, including the buccal mucosa, the soft palate, the ventral surface of the tongue, the floor of the mouth, and the labial mucosa. On the gingiva, the condition frequently manifests as desquamative gingivitis, characterised by intensely erythematous, glazed, and friable gums that bleed easily upon gentle brushing or periodontal probing. A classical diagnostic sign is Nikolsky's sign, where tangential sliding pressure applied with an instrument or finger to clinically normal-appearing perilesional mucosa causes the superficial epithelium to shear and peel away.

Diagnostic Pathways: Biopsy, Immunofluorescence, and Differential Diagnosis

Establishing an accurate diagnosis requires a structured, multi-modal clinical pathway overseen by an oral medicine specialist or oral and maxillofacial surgeon. Because clinical signs overlap with several other vesiculobullous and ulcerative disorders, histopathological and immunological verification is mandatory. Routine haematological panels, alongside dental radiography where necessary, help rule out concurrent systemic pathology and odontogenic sources of inflammation. However, the definitive diagnosis rests on tissue biopsy and serological antibody profiling.

A proper diagnostic workup requires two separate biopsy specimens taken from the oral cavity. The first is an incisional or punch biopsy obtained from the perilesional margin (encompassing the edge of an erosion alongside intact epithelium) fixed in standard formalin for haematoxylin and eosin (H&E) light microscopy. Histopathology demonstrates suprabasal acantholysis, with detached, rounded keratinocytes (Tzanck cells) floating within the intraepithelial cleft and a characteristic row of intact basal cells remaining attached to the basement membrane, resembling a 'tombstone' appearance. The second specimen, taken from clinically normal perilesional tissue, is placed in Michel's transport medium or snap-frozen for direct immunofluorescence (DIF) microscopy.

Direct immunofluorescence serves as the gold standard, demonstrating deposition of IgG antibodies and often complement protein C3 in a continuous, intercellular 'fishnet' or 'chicken-wire' pattern throughout the squamous epithelium. Serological testing via enzyme-linked immunosorbent assay (ELISA) or indirect immunofluorescence (IIF) is performed concurrently to quantify circulating anti-desmoglein 3 and anti-desmoglein 1 autoantibody titres. Differential diagnosis is critical to distinguish pemphigus vulgaris from mucous membrane pemphigoid (which features subepithelial splitting), oral lichen planus, linear IgA disease, major aphthous stomatitis, and paraneoplastic pemphigus.

Disease Staging and Clinical Severity Scoring

Standardised disease staging is essential for guiding therapeutic intensity, monitoring clinical remission, and establishing prognosis. Internationally validated scoring systems, such as the Pemphigus Disease Area Index (PDAI) and the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS), quantify disease severity based on the number, size, and anatomical distribution of active erosions and blisters across mucosal and cutaneous surfaces.

Clinically, pemphigus vulgaris is classified into mucosal-dominant and mucocutaneous forms. In the mucosal-dominant variant, autoantibodies are almost exclusively targeted against desmoglein 3, confining blisters and ulcerations to the oral cavity, pharynx, larynx, and occasionally the oesophagus or genital mucosa. In the mucocutaneous variant, autoantibodies against both desmoglein 3 and desmoglein 1 are present, leading to extensive blistering across the trunk, scalp, face, and intertriginous skin folds in addition to severe oral ulceration. Tracking scoring indices over time provides clinicians with an objective metric to differentiate between active disease flares, partial control, and complete clinical remission off therapy.

Evidence-Based Medical and Topical Treatments

The modern therapeutic paradigm for pemphigus vulgaris is anchored in systemic immunosuppression to halt pathogenic autoantibody production and control mucosal inflammation. Historically, high-dose systemic corticosteroids (such as oral prednisolone) served as the solitary cornerstone of induction therapy. While highly effective at rapidly arresting epithelial separation, long-term high-dose steroid regimens carry profound systemic risks, including osteoporosis, diabetes mellitus, hypertension, adrenal suppression, and opportunistic infections.

Consequently, contemporary international consensus guidelines strongly advocate combining systemic corticosteroids with steroid-sparing immunosuppressive agents or targeted biological therapy early in the disease course. Conventional steroid-sparing agents include azathioprine and mycophenolate mofetil, both of which inhibit purine synthesis in proliferating lymphocytes. More recently, rituximab—a monoclonal antibody that targets CD20 receptors on B lymphocytes—has emerged as a first-line therapy for moderate-to-severe pemphigus vulgaris, demonstrating high rates of complete clinical remission and significantly reducing cumulative steroid exposure.

Adjunctive topical therapies play a vital supportive role for localized oral ulceration and desquamative gingivitis. High-potency topical corticosteroids (such as clobetasol propionate or betamethasone sodium phosphate dissolved as a mouthwash) and topical calcineurin inhibitors (such as tacrolimus) can be applied directly to stubborn mucosal lesions. These topical agents help alleviate local pain, accelerate mucosal re-epithelialisation, and allow for a more rapid taper of systemic medications without inducing systemic side effects.

Step-by-Step Clinical Assessment and Biopsy Procedure

When an oral medicine specialist suspects pemphigus vulgaris, the clinical consultation follows a meticulous, systematic sequence. The practitioner conducts a detailed history covering the timeline of oral blisters, swallowing difficulties, skin involvement, and previous treatment responses. An exhaustive clinical examination is then performed under high-illumination surgical lighting, inspecting every oral subsite, palpating cervical lymph nodes, and gently checking for Nikolsky's sign using a sterile instrument.

If a biopsy is indicated, the procedure is typically carried out under local anaesthesia during the same appointment. The clinician administers local anaesthetic containing adrenaline via gentle infiltration situated slightly away from the chosen biopsy site to avoid hydrodissection or mechanical artefact within the fragile epithelium. Using a 4 mm to 6 mm punch or an elliptical scalpel incision, the clinician harvests the perilesional tissue margin, handling the tissue specimen with extreme gentleness using non-toothed forceps to prevent crushing the delicate epithelium.

The harvested tissue is divided precisely; one portion is immediately immersed in neutral buffered formalin for standard histopathology, and the second is placed into Michel's transport solution for immunofluorescence testing. Haemostasis is achieved using delicate resorbable sutures or gentle pressure with gauze. Blood is subsequently drawn for serum anti-desmoglein ELISA testing. The patient is provided with detailed written post-operative instructions and scheduled for a suture check and multidisciplinary review once laboratory results are finalised.

Post-Biopsy Recovery, Aftercare, and Oral Hygiene Care

Recovery from an oral biopsy is usually straightforward, with mild local discomfort that typically responds to simple analgesics such as paracetamol. Patients should expect slight swelling and tenderness at the biopsy site for 3 to 7 days. Normal healing involves the formation of a yellowish-white fibrinous membrane over the surgical site, which must not be disturbed or scrubbed away. However, persistent bleeding, worsening throbbing pain, foul taste, or expanding redness warrant immediate clinical review.

Maintaining meticulous oral hygiene is both critical and challenging in patients suffering from extensive pemphigus vulgaris mouth blisters and desquamative gingivitis. Plaque accumulation exacerbates local gingival inflammation, creating a destructive cycle of pain and tissue friability. Patients should use an ultra-soft surgical toothbrush, warming the bristles under warm tap water prior to use to maximize softness. Standard foaming toothpastes containing sodium lauryl sulphate (SLS) should be strictly replaced with non-foaming, SLS-free formulations to avoid chemical irritation.

Dietary modifications are equally crucial during active erosive phases. Patients should consume a soft, bland, room-temperature diet rich in lean proteins and micronutrients to support tissue repair. Coarse, crusty, highly acidic (citrus, tomato), salty, and heavily spiced foods must be avoided entirely. In cultural contexts where paan, betel nut, or chewing tobacco are consumed, absolute cessation is mandatory, as these substances exert profound mechanical trauma and chemical toxicity on an already compromised mucosal epithelium.

Complications, Secondary Infections, and Monitoring

Uncontrolled oral pemphigus vulgaris carries substantial risks of both local and systemic complications. The extensive loss of the mucosal barrier leaves underlying connective tissues highly susceptible to secondary microbial invasion. Oral candidiasis (thrush) is particularly common, especially when patients are managed on long-term systemic or topical corticosteroids. Secondary bacterial colonization by Staphylococcus aureus or Streptococcus species can dramatically worsen mucosal necrosis, intensify pain, and delay tissue regeneration.

Severe, widespread oral ulceration significantly impairs normal mastication and deglutition, leading to progressive nutritional deficits, involuntary weight loss, and dehydration. Long-term management requires vigilant, continuous monitoring by a multidisciplinary team combining oral medicine consultants, dermatologists, and primary care physicians. Regular haematological profiling, liver and renal function panels, bone density (DEXA) scans, and blood glucose monitoring are necessary to detect and mitigate the adverse effects of prolonged immunosuppressive and corticosteroid therapy.

Urgent Red Flags and When to Seek Immediate Care

While oral pemphigus vulgaris is generally managed as a chronic outpatient condition, certain clinical developments represent medical emergencies requiring urgent hospital evaluation. Patients must be educated on critical red-flag signs that indicate rapid disease acceleration, profound secondary infection, or life-threatening systemic decompensation.

Immediate emergency medical assessment is required if the patient develops an inability to swallow liquids leading to signs of acute dehydration, or if blisters and erosions suddenly spread extensively across the cutaneous surface, resembling a severe burn. Systemic red flags include high fever, rigors, lethargy, rapidly spreading mucosal sloughing, or purulent exudates suggesting bacterial sepsis. Furthermore, signs of hoarseness, stridor, or respiratory distress indicate potential laryngeal or pharyngeal involvement, demanding emergency airway and otorhinolaryngology assessment.

Evidence and further reading

Clinical management of oral pemphigus vulgaris is guided by international evidence-based recommendations established by consensus panels, including the British Association of Dermatologists, the European Academy of Dermatology and Venereology (EADV), and position statements published in the International Journal of Oral and Maxillofacial Surgery and the Journal of the American Academy of Dermatology. High-level evidence synthesised across systematic reviews and multicentre randomised controlled trials consistently demonstrates that early intervention with targeted B-cell depletion therapy (rituximab) combined with short-course corticosteroids achieves superior remission rates and fewer severe adverse events compared to prolonged high-dose corticosteroid monotherapy.

The diagnostic protocols incorporating direct immunofluorescence alongside anti-desmoglein ELISA serology are endorsed by the European Dermatology Forum and international bullous disease working groups as the undisputed standard for disease identification and therapeutic monitoring. Patients and clinicians seeking detailed guidance on clinical trials, patient support networks, and management guidelines are directed to resources maintained by the International Pemphigus and Pemphigoid Foundation (IPPF), the British Association of Dermatologists guidelines library, and the National Institute for Health and Care Excellence (NICE) clinical evidence summaries.